Oliver Lagore Vanvalin Investment Group Acquires 1,535 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oliver Lagore Vanvalin Investment Group increased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 71.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,694 shares of the medical equipment provider’s stock after purchasing an additional 1,535 shares during the quarter. Oliver Lagore Vanvalin Investment Group’s holdings in Intuitive Surgical were worth $1,246,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of ISRG. RB Capital Management LLC boosted its stake in shares of Intuitive Surgical by 4.4% in the 1st quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock valued at $523,000 after purchasing an additional 73 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Intuitive Surgical by 0.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock worth $285,603,000 after purchasing an additional 5,233 shares during the period. Baird Financial Group Inc. lifted its position in shares of Intuitive Surgical by 2.3% in the 1st quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock worth $6,362,000 after purchasing an additional 481 shares during the period. Brown Brothers Harriman & Co. lifted its position in shares of Intuitive Surgical by 576.7% in the 1st quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock worth $122,000 after purchasing an additional 346 shares during the period. Finally, Covestor Ltd lifted its position in shares of Intuitive Surgical by 50.4% in the 1st quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 140 shares during the period. 83.64% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have issued reports on ISRG. Royal Bank of Canada lifted their price objective on shares of Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a report on Wednesday, January 24th. Truist Financial upped their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 24th. Wells Fargo & Company upped their price target on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research report on Friday, January 19th. Mizuho upped their price target on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Finally, Citigroup upped their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Five research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $375.70.

Intuitive Surgical Stock Performance

Shares of ISRG traded down $0.76 during trading hours on Thursday, hitting $373.41. The company had a trading volume of 1,128,150 shares, compared to its average volume of 1,627,749. The firm has a fifty day moving average price of $387.56 and a 200-day moving average price of $342.39. The stock has a market capitalization of $132.36 billion, a price-to-earnings ratio of 74.39, a P/E/G ratio of 5.88 and a beta of 1.36. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.48 by $0.12. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The firm had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the firm earned $0.91 EPS. Intuitive Surgical’s quarterly revenue was up 16.6% compared to the same quarter last year. Research analysts anticipate that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the transaction, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the business’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.15, for a total value of $1,598,307.70. Following the completion of the transaction, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Marshall Mohr sold 108,790 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now owns 26,877 shares of the company’s stock, valued at $10,349,795.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is owned by insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.